GO
Loading...

Pharmaceuticals

More

  • Jan 20- Johnson& Johnson surprised investors by detailing the degree to which a strong dollar will hurt sales abroad this year, and industry watchers say Wall Street is underestimating the likely hit to other U.S.-based rivals such as Pfizer Inc and Merck& Co.. He predicted the stronger dollar will take a bigger bite out of other drugmakers' earnings than many...

  • Bristol-Myers names Caforio as CEO Tuesday, 20 Jan 2015 | 5:47 PM ET

    NEW YORK— Drugmaker Bristol-Myers Squibb said Tuesday that has named its chief operation officer, Giovanni Caforio, as its new CEO. Cornelius was CEO of Bristol-Myers Squibb Co. from 2006 to 2010. He became chairman in 2008, moving to non-executive chairman in May 2010. Shares of Bristol-Myers Squibb rose 14 cents to $62.45 Tuesday.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • Merck's 'not up for a big deal in 2015': Chair  Tuesday, 20 Jan 2015 | 11:30 AM ET

    Merck Chairman Karl-Ludwig Kley sheds some light on his company's plans for 2015, a year he forecasts will see less pharmaceutical M&A activity than 2014.

  • Davos: Who needs a 'wake up call'?  Tuesday, 20 Jan 2015 | 11:25 AM ET

    Discussing the current state of Europe at Davos 2015, Karl-Ludwig Kley, chairman of Merck says the lack of coordination and cohesion in European businesses is the current problem.Meanwhile political leaders need a wake-up call.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • Regeneron CEO: Choice, not price best for patients  Tuesday, 20 Jan 2015 | 7:41 AM ET

    CNBC's Meg Tirrell and Leonard Schleifer, Regeneron president & CEO, talk about providing fair drug pricing for patients.

  • LONDON, Jan 20- the international charity Medecins Sans Frontieres urged drugmakers GlaxoSmithKline and Pfizer on Tuesday to slash the price of their pneumococcal vaccines to $5 per child in poor countries. Pfizer also said its pneumococcal shot, Prevenar 13, was highly complex. It said GSK and Pfizer had together reported more than $19 billion in global...

  • TRENTON, N.J.— Drugmaker AbbVie Inc. said Monday that its new, all-pill hepatitis C combo treatment has been approved for patients in the 28 European Union member countries. The company said the European Commission granted marketing authorization for the combination of Viekirax and Exviera. It's already approved in EU nonmembers Switzerland, Norway, Iceland...

  • Elder statesman of Sweden's Wallenberg dynasty dies Monday, 19 Jan 2015 | 7:57 AM ET

    STOCKHOLM, Jan 19- Peter Wallenberg, the elder statesman of Sweden's business dynasty, died on Monday, the family investment foundation said. Peter Wallenberg, who was 88, had been chairman of the family's listed investment vehicle Investor from 1982 to 1997. More recently he had stepped back from day-to-day business activities. Peter Wallenberg has passed...

  • DES MOINES, Iowa— Nearly $86 million has been awarded to four companies to support job creation and expansion projects in the state, the Iowa Economic Development Authority announced Friday. The grants will aid projects in Davenport, Ames, Charles City and Burlington, the board said. —Alter Trading Corporation, a metal recycling company in Davenport:...

  • Aetna Inc. said Friday that it's reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment. Aetna's decision follows moves by two huge prescription benefit managers, Express Scripts Holdings Co. and CVS Health Corp., to wring big discounts from makers of a...

  • If you could be any other CEO, who would you be? Friday, 16 Jan 2015 | 12:14 PM ET
    Tesla Motors CEO Elon Musk speaking in Detroit, January 13, 2015.

    At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.

  • LONDON, Jan 16- GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with Reuters, Andrew Witty also said he and his team had spent "a few days" exploring whether the drugmaker...

  • *Consumer more tenable as standalone business after Novartis deal. Chief Executive Andrew Witty told Reuters the group's large consumer health business would be more viable as a standalone operation following the conclusion of a $20 billion asset swap with Novartis, especially if it bought additional assets. "Post- Novartis, particularly if we did more...

  • SAN FRANCISCO/ WASHINGTON Jan 15- U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans. Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that...

  • *Asset could be worth up to 2 bln euros- Bloomberg. FRANKFURT, Jan 15- German drugmaker Boehringer Ingelheim said it is considering the sale of its U.S.-based generics unit Roxane Labs to put a stronger focus on the development and sale of new pharmaceuticals. A company spokeswoman said Boehringer was not a specialist in generics and was therefore considering...

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....